Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest update is out from Revance Therapeutics (RVNC).
Revance Therapeutics, Inc. has extended its agreement with Ajinomoto Bio-Pharma Services until December 31, 2027, for manufacturing services related to DAXXIFY® at their San Diego facility, with updated terms regarding product conformity and delay remedies. Additionally, the company’s President, Mr. Sjuts, will step down, receiving a severance package, which includes 18 months of his base salary and health benefits, and will remain as a consultant for a year to ensure a smooth transition and allow his equity awards to continue vesting.
For an in-depth examination of RVNC stock, go to TipRanks’ Stock Analysis page.